Tags

Type your tag names separated by a space and hit enter

Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.

Abstract

OBJECTIVE

Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy.

MATERIAL

The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 microg).

RESULTS

Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation. An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001). After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated.

CONCLUSION

As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology, Pomeranian Academy of Medicine, Szczecin, Poland. ldoroz@uoo.univ.szczecin.pl

    Source

    Gynecologic oncology 93:2 2004 May pg 320-7

    MeSH

    Aged
    Antineoplastic Combined Chemotherapy Protocols
    Blood Platelets
    Cisplatin
    Cyclophosphamide
    Dietary Supplements
    Erythrocytes
    Female
    Glutathione Peroxidase
    Hair
    Humans
    Malondialdehyde
    Middle Aged
    Ovarian Neoplasms
    Oxidative Stress
    Selenium

    Pub Type(s)

    Clinical Trial
    Controlled Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    15099940

    Citation

    Sieja, Krzysztof, and Małgorzata Talerczyk. "Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy." Gynecologic Oncology, vol. 93, no. 2, 2004, pp. 320-7.
    Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol. 2004;93(2):320-7.
    Sieja, K., & Talerczyk, M. (2004). Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecologic Oncology, 93(2), pp. 320-7.
    Sieja K, Talerczyk M. Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy. Gynecol Oncol. 2004;93(2):320-7. PubMed PMID: 15099940.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. AU - Sieja,Krzysztof, AU - Talerczyk,Małgorzata, PY - 2002/09/27/received PY - 2003/12/02/revised PY - 2003/12/16/accepted PY - 2004/4/22/pubmed PY - 2004/6/21/medline PY - 2004/4/22/entrez SP - 320 EP - 7 JF - Gynecologic oncology JO - Gynecol. Oncol. VL - 93 IS - 2 N2 - OBJECTIVE: Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy. MATERIAL: The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 microg). RESULTS: Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.05) and hair (P < 0.05) was significantly higher than in the control group. It has also been found that Se concentration in serum was significantly increased after 2 (P < 0.0000) and 3-months' (P < 0.0000) length of supplementation, as compared to the values after 1 month. In the hair of patients receiving this supplementation, an insignificantly higher concentration of this microelement was found after 2 (NS) and 3 months (NS) in comparison to the concentration after 1 month. The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0.0015) and 3 months' (P < 0.0038) supplementation. An increase of the concentration of malondialdehyde (MDA) following the administration of Se after 2 months (P < 0.0363) and 3 months (P < 0.0489) was found to be significant. The increase of MDA calculated into platelet count was found to be significant after 3 months (P 0.0477) of Se supplementation. Se administration for 3 months resulted in the significant increase of white blood cells (WBC) (P < 0.0001). After 2 and 3 months of Se administration, a significant decrease of hair loss (P < 0.0000; P < 0.0392, respectively), flatulence (P < 0.0000; P< 0.0000), abdominal pain (P < 0.0006; P < 0.0202), weakness (P < 0.0001; P < 0.0000), malaise (P < 0.0017; P < 0.0000), loss of appetite (P < 0.0000; P < 0.0000) was stated. CONCLUSION: As a result of this clinical trial, we conclude that there are beneficial effects caused by ingesting selenium, as a supportive element in chemotherapy. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/15099940/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090825803008874 DB - PRIME DP - Unbound Medicine ER -